Johnson & Johnson

On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE:JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc baby powder for her ovarian cancer. The verdict lands as the company also fights over whether...

Johnson & Johnson (NYSE:JNJ) has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder. What Happened: A Minnesota jury awarded Anna Jean Houghton Carley, a mother of three, $65.5 million on Friday. Carley contended...

U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07, while the Dow edged down 0.03% to 41,989.96. Market optimism was supported by a 0.7% rise in U.S. construction spending for February. Even so,...

As the market begins to shift its focus away from tech, CNBC’s Jim Cramer has identified several potential winners, CNBC reports. Cramer has highlighted a few sectors that could benefit from this shift. He believes that the market is currently in a “stock picker’s market”...

Shareholders of Johnson & Johnson (NYSE:JNJ) will soon have the opportunity to exchange their shares for those of Kenvue Inc. (NYSE:KVUE), the consumer health company that spun off from J&J two months ago, CNBC reports. What Happened: J&J, which owns nearly 90% of Kenvue shares, plans...

The U.S. stock market is seeing some modest selling on Tuesday morning after a series of largely uneventful sessions last week. Two hours into the trading day, the S&P 500 was down around 0.75% and the Nasdaq had pared 0.90%. In a market that has been attracting a good deal of pessimistic...

Regulation is among the factors inhibiting the flow of capital to cannabis innovation. Institutions are afraid to invest, and “big pharma is not coming in as we would like to see happen.” That is according to Aras Azadian, who joined the Benzinga Cannabis Capital Conference in Miami...

Johnson & Johnson (NYSE: JNJ) says it has settled most of the lawsuits in the anti-psychotic drug Risperdal cases and has recorded $800 million in expenses in connection with the agreement. The medical devices and pharmaceuticals maker had almost 9000 cases over the Risperdal drug,...

Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagnostic tests has outperformed some of the largest healthcare companies over the last five...

The cover story in this weekend's Barron's suggests how to play travel stocks as the recovery falters. Other featured articles discuss banking stocks with steady dividends, stocks that will benefit from share buybacks and why the boom in energy stocks may be over. Also, see the prospects...

The earnings parade continues, with a steady flow of solid corporate results helping Wall Street recover from Monday’s huge plunge. In fact, the major indices are basically back where they were Friday after two crazy days, making it look like Monday and Tuesday never happened.  The...

The cover story in this weekend's Barron's offers 42 bargain stock picks from the Barron's Roundtable. Other featured articles discuss disappearing Chinese stocks, the next big thing in biotech and themes to watch for in big tech earnings. Also, see the prospects for a sporting goods...

On Saturday, Johnson & Johnson (NYSE: JNJ) said it would end the manufacture and sale of opioids nationwide in a $230 million settlement with the New York state, Reuters reports.  J&J will not face the jury trial scheduled to begin on Tuesday on Long Island with...

On Tuesday, Johnson & Johnson (NYSE: JNJ) reported $100 million in first-quarter sales of its single shot Covid-19 vaccine that's on hold in the U.S. due to a rare and potentially life-threatening blood clotting disorder which has been also related to AstraZeneca (NASDAQ: AZN) vaccine which...

If stocks fall on back-to-back days for the first time this month, you can probably blame an old culprit: Covid. Yesterday was the biggest down day in a month, and it looks like the pullback is seeing a little follow-through, with stocks under pressure in pre-market trading despite solid earnings...